- Home
- NKSH vs KROS Comparison
NKSH vs KROS Comparison
Compare NKSH & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKSH | KROS |
|---|---|---|
| Founded | 1891 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 222.3M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NKSH | KROS |
|---|---|---|
| Price | $34.80 | $10.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 25.1K | ★ 299.5K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | 100.81 | ★ 146.00 |
| EPS | ★ 0.78 | N/A |
| Revenue | $8,176,000.00 | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | $44.74 | ★ N/A |
| Revenue Growth | ★ 9.39 | N/A |
| 52 Week Low | $24.74 | $9.79 |
| 52 Week High | $40.00 | $22.55 |
Technical Indicators
Market Signals| Indicator | NKSH | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 47.62 | 39.31 |
| Support Level | $34.32 | $9.79 |
| Resistance Level | $38.09 | $12.43 |
| Average True Range (ATR) | 0.78 | 0.55 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 71.19 | 29.89 |
Price Performance
Historical ComparisonAbout NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.